Evidence map›Paper›PMID 36127323›Full record

ArticleCell death & disease2022

Primary cilia contribute to the aggressiveness of atypical teratoid/rhabdoid tumors.

Lena Blümel, Nan Qin, Johannes Berlandi, Eunice Paisana, Rita Cascão, Carlos Custódia, David Pauck, Daniel Picard, Maike Langini, Kai Stühler and 19 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. NAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 8 institutions in 3 countries.

Lena BlümelDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University Düsseldorf, Medical Faculty, and University Hospital Düsseldorf, Düsseldorf, Germany. lena.bluemel@med.uni-duesseldorf.de.
Nan QinDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University Düsseldorf, Medical Faculty, and University Hospital Düsseldorf, Düsseldorf, Germany.
Johannes BerlandiInstitute of Neuropathology, University Hospital Münster, Münster, Germany.
Eunice PaisanaInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.
Rita CascãoInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.
Carlos CustódiaInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.
David PauckDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University Düsseldorf, Medical Faculty, and University Hospital Düsseldorf, Düsseldorf, Germany.
Daniel PicardDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University Düsseldorf, Medical Faculty, and University Hospital Düsseldorf, Düsseldorf, Germany.
Maike LanginiGerman Cancer Consortium (DKTK), partner site Essen/Düsseldorf, Düsseldorf, Germany.ORCID 0000-0001-8622-3261
Kai StühlerMolecular Proteomics Laboratory, Biological and Medical Research Center (BMFZ), Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Frauke-Dorothee MeyerDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University Düsseldorf, Medical Faculty, and University Hospital Düsseldorf, Düsseldorf, Germany.
Sarah GöbbelsDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University Düsseldorf, Medical Faculty, and University Hospital Düsseldorf, Düsseldorf, Germany.
Bastian MalzkornInstitute of Neuropathology, Heinrich Heine University Düsseldorf, Medical Faculty, and University Hospital Düsseldorf, Düsseldorf, Germany.
Max C LiebauDepartment of Pediatrics, Center for Family Health, Center for Rare Diseases and Center for Molecular Medicine, University Hospital Cologne and Faculty of Medicine, University of Cologne, Cologne, Germany.
João T BarataInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.
Astrid JeibmannInstitute of Neuropathology, University Hospital Münster, Münster, Germany.
Kornelius KerlDepartment of Pediatric Hematology and Oncology, University Hospital Münster, Münster, Germany.
Serap ErkekHopp Childrens Cancer Center (KiTZ), Heidelberg, Germany.
Marcel KoolHopp Childrens Cancer Center (KiTZ), Heidelberg, Germany.
Stefan M PfisterHopp Childrens Cancer Center (KiTZ), Heidelberg, Germany.
Pascal D JohannHopp Childrens Cancer Center (KiTZ), Heidelberg, Germany.
Michael C FrühwaldSwabian Childrens´ Cancer Center, Pediatrics and Adolescent Medicine, University Medical Center, Augsburg, Germany.
Arndt BorkhardtDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University Düsseldorf, Medical Faculty, and University Hospital Düsseldorf, Düsseldorf, Germany.ORCID 0000-0002-6121-4737
Guido ReifenbergerGerman Cancer Consortium (DKTK), partner site Essen/Düsseldorf, Düsseldorf, Germany.
Claudia C FariaInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.
Ute FischerDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University Düsseldorf, Medical Faculty, and University Hospital Düsseldorf, Düsseldorf, Germany.ORCID 0000-0002-2455-2489
Martin Hasselblatt *Institute of Neuropathology, University Hospital Münster, Münster, Germany.
Jasmin Bartl *Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University Düsseldorf, Medical Faculty, and University Hospital Düsseldorf, Düsseldorf, Germany.ORCID 0000-0002-8737-2610
Marc Remke *Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University Düsseldorf, Medical Faculty, and University Hospital Düsseldorf, Düsseldorf, Germany. marc.remke@med.uni-duesseldorf.de.ORCID 0000-0002-9404-9993
Düsseldorf University Hospital · DEUniversity of Lisbon · PTGerman Cancer Research Center · DEUniversity Hospital Münster · DEDeutschen Konsortium für Translationale Krebsforschung · DEUniversität Hamburg · DEUniversity Hospital Augsburg · DEUniversity of Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atypical teratoid/rhabdoid tumor (AT/RT) is a highly malignant brain tumor in infants that is characterized by loss of nuclear expression of SMARCB1 or SMARCA4 proteins. Recent studies show that AT/RTs comprise three molecular subgroups, namely AT/RT-TYR, AT/RT-MYC and AT/RT-SHH. The subgroups show distinct expression patterns of genes involved in ciliogenesis, however, little is known about the functional roles of primary cilia in the biology of AT/RT. Here, we show that primary cilia are present across all AT/RT subgroups with specific enrichment in AT/RT-TYR patient samples. Furthermore, we demonstrate that primary ciliogenesis contributes to AT/RT biology in vitro and in vivo. Specifically, we observed a significant decrease in proliferation and clonogenicity following disruption of primary ciliogenesis in AT/RT cell line models. Additionally, apoptosis was significantly increased via the induction of STAT1 and DR5 signaling, as detected by proteogenomic profiling. In a Drosophila model of SMARCB1 deficiency, concomitant knockdown of several cilia-associated genes resulted in a substantial shift of the lethal phenotype with more than 20% of flies reaching adulthood. We also found significantly extended survival in an orthotopic xenograft mouse model of AT/RT upon disruption of primary ciliogenesis. Taken together, our findings indicate that primary ciliogenesis or its downstream signaling contributes to the aggressiveness of AT/RT and, therefore, may constitute a novel therapeutic target.

Indexed as

Brain NeoplasmsRhabdoid TumorTeratomaAnimalsCiliaDNA HelicasesHumansMiceNuclear ProteinsSignal TransductionTranscription FactorsDNA HelicasesNuclear ProteinsSMARCA4 protein, humanTranscription Factors

Identifiers

PMID36127323
PMCPMC9489777
OpenAlexW4296425929

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.